secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2024-03-01T23:59:59+00:00
Accession:  0001493152-24-008493
Event type: other_material
Sentiment:  negative
Materiality: 0.50
Item codes: 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal terminates license agreements with Kansas State due to futility; retains CDI-988
--------------------------------------------------------------------------------

- On Feb 28, 2024, Cocrystal notified Kansas State University Research Foundation of termination of two License Agreements (Feb 12, 2020 and Apr 19, 2020), effective March 29, 2024.
- Termination due to determination that further development under the Agreements would be futile.
- Wholly owned compound CDI-988 (pan-viral for coronavirus and norovirus) is not affected and is in Phase 1 clinical trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315224008493/0001493152-24-008493-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315224008493/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-008493

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer